Theriva Biologics Inc (TOVX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2019 | 12-2018 | 12-2017 | 12-2016 | 12-2015 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -15,380 | -13,421 | -15,492 | -27,803 | -44,785 |
| Depreciation Amortization | 240 | 272 | 245 | 157 | 72 |
| Accounts payable and accrued liabilities | 1,282 | -987 | 27 | -2,420 | 3,417 |
| Other Working Capital | 855 | -2,192 | 2,372 | 7,148 | -5,536 |
| Other Operating Activity | -870 | -951 | -7,356 | -4,983 | 7,942 |
| Operating Cash Flow | $-13,873 | $-17,279 | $-20,204 | $-27,901 | $-38,890 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | N/A | -7 | -212 | -569 | -501 |
| Investing Cash Flow | $N/A | $-7 | $-212 | $-569 | $-501 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | N/A | 29,088 | 6,524 | 27,323 | 46,041 |
| Other Financing Activity | 0 | 0 | 11,953 | -616 | -3,357 |
| Financing Cash Flow | $N/A | $29,088 | $18,477 | $26,707 | $42,684 |
| Beginning Cash Position | 28,918 | 17,116 | 19,055 | 20,818 | 17,525 |
| End Cash Position | 15,045 | 28,918 | 17,116 | 19,055 | 20,818 |
| Net Cash Flow | $-13,873 | $11,802 | $-1,939 | $-1,763 | $3,293 |
| Free Cash Flow | |||||
| Operating Cash Flow | -13,873 | -17,279 | -20,204 | -27,901 | -38,890 |
| Capital Expenditure | N/A | -7 | -212 | -569 | -501 |
| Free Cash Flow | -13,873 | -17,286 | -20,416 | -28,470 | -39,391 |